Xiamen Kingdomway Group Company (SZSE: 002626)
Health Care · Pharmaceuticals · CN
CN¥16.63
+3.29% today · -13.6% 1Y
Xiamen Kingdomway Group Company (SZSE: 002626) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.51B and employs 2,184 people.
Over the last twelve months the share price has lost 13.6%, trading between 12.90 and 22.44.
Tweenvest scores Xiamen Kingdomway Group Company across four factors: quality 71/100, value 53/100, growth 26/100, dividend 44/100. Its strongest factor is quality.
002626 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.51B
- Revenue (TTM)
- $485.91M
- P/E
- 36.04
- EPS
- 0.46
- Dividend yield
- 2.41%
- Beta (5Y)
- 0.38
- 52-week high
- CN¥22.44
- 52-week low
- CN¥12.90
- Avg volume (3M)
- —
- Shares outstanding
- 609.94M
- Employees
- 2,184
- Next earnings
- —
About Xiamen Kingdomway Group Company
Xiamen Kingdomway Group Company operates as a global producer and distributor of a variety of nutritional and health-focused goods. The company's offerings encompass a selection of fundamental raw ingredients, notably coenzyme Q10, Vitamin A, Vitamin D3, DHA derived from microalgae, and plant-based ARA. Furthermore, it manufactures ready-to-use dietary supplements and specialized sports nutrition products. Originally established in 1997, the firm was previously recognized as Xiamen Jindawei Vitamin Co., Ltd., and maintains its principal offices in Xiamen, China.
- ISIN
- CNE1000018X4
- Founded
- 1997
- Listed since
- Oct 28, 2011
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,245.90 | -0.76% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.18 | +0.35% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.48 | -1.36% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.20 | -1.70% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.54 | -1.52% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.96 | -0.41% |
Figures last refreshed Aug 18, 2026.